Blue Jet Healthcare Limited · NSE:BLUEJET
Blue Jet Healthcare — Q1 FY26 Earnings Presentation
37 slides from Blue Jet Healthcare's earnings presentation, Jul 22, 2025
Slide 1: Exchange filing cover letter for analyst presentation
July 22, 2025 To, BSE Limited National Stock Exchange of India Limited Phiroze Jeejebhoy Towers “Exchange Plaza” Dalal Street Bandra-Kurla Complex, Bandra (East) Mumbai - 400 001 Mumbai - 400051 Scrip Code (BSE): 544009 Symbol: BLUEJET Sub: Analysts/Investors Presentation on Financial Results for th
Slide 2: Investor Presentation Q1 FY26
Investor Presentation Q1 FY26 1
Slide 3: Disclaimer
Disclaimer The Presentation is to provide the general background information about the Company’s activities as at the date of the Presentation. The information contained herein is for general information purposes only and based on estimates and should not be considered as a recommendation that any i
Slide 4: Table of Content
Table of Content 1 Q1 FY26 Financials 2 Company at a Glance 3 Contrast Media Intermediates 4 High Intensity Sweeteners 5 Pharma Intermediates & API 6 R&D Capabilities 7 Growth Strategy 8 Management and Board of Directors 3
Slide 5: Q1 FY26 Financials
‘| Q1 FY26 Financials Ny @ in roy Pe, k ~ >» gl sing Bi 2 v ‘ uff
Slide 6: Q1 FY26 Earnings Highlights
Q1 FY26 Earnings Highlights Financial Highlights ✓ Revenue from operations for Q1 FY26 stood at Rs. 3,548 mn which grew 4.2% QoQ compared to Rs. 3,404 mn in Q4 FY25; up 117.8% on YoY basis compared to Rs. 1,629 mn in Q1 FY25. This growth is mainly driven by higher sales in PI & API product category
Slide 7: Q1 FY26 vs Q1 FY25 Financial Performance – Key Metrics
Q1 FY26 Vs Q1 FY25 Financial Performance – Key Metrics Revenue from Operations** – Growth Trends (Rs Mn) YoY 50.7% -0.2% 251.9% 356.4% 118.6% Growth: Q1 FY25 Q1 FY26 3,537 2,120 1,618 972 645 602 350 349 21 97 Contrast media intermediates High-intensity sweetners Pharma intermediates and API Others*
Slide 8: FY25 vs FY24 Financial Performance – Key Metrics
FY25 Vs FY24 Financial Performance – Key Metrics Revenue from Operations** – Growth Trends (Rs Mn) YoY -15.8% 4.1% 387.8% 350.3% 44.6% Growth: FY24 FY25 10,243 7,084 4,799 4,039 4,622 1,282 1,335 947 55 247 Contrast media intermediates High-intensity sweetners Pharma intermediates and API Others* To
Slide 9: Profit and Loss Statement
Profit and Loss Statement Particulars (Rs. Mn) Q1 FY26 Q4 FY25 QoQ Q1 FY25 YoY Revenue from Operations 3,548 3,404 4.2% 1,629 117.8% Cost Of Goods Sold 1,829 1,535 738 Gross Profit 1,719 1,870 -8.1% 891 92.9% Gross Margin 48.4% 54.9% 54.7% Employee benefits expenses 174 160 148 Other expenses 334 31
Slide 10: Financial Performance over the years – Key Metrics
Financial Performance over the years – Key Metrics Revenue from Operations** – Growth Trends (Rs Mn) CAGR: 3.4% 7.8% 82.4% 269.2% 26.2% 10,243 7,185 7,084 6,768 4,778 5,070 4,799 4,622 4,942 3,536 4,039 1,759 1,282 1,335 987 1,575 418 412 947 340 1.33 3 16 55 247 Contrast media intermediates High-in
Slide 11: Financials for the last four years
Financials for the last four years Summary Statement of Profit and Loss Summary Statement of Assets and Liabilities Particulars (Rs. Mn) FY21 FY22 FY23 FY24 FY25 Particulars (Rs. Mn) FY21 FY22 FY23 FY24 FY25 I. Assets Revenue from Operations 4,989 6,835 7,210 7,116 10,300 Property, plant and equipme
Slide 12: Shareholder Information
Shareholder Information Shareholding as on 30th June 2025 Share Information as on 30th June 2025 NSE Ticker BLUEJET MF Others BSE Ticker 544009 11.1% Other DIIs 0.5% Market Cap (INR Cr) (NSE) 15,226 0.5% FII % free-float 14% 1.9% Free-float market cap (INR Cr) 2,132 Cash & Cash Equivalents + Treasur
Slide 13: Company at a Glance
. » gf Z 4 Company ata > AF Glance v SS 2
Slide 14: Our Journey
Our Journey • Established Jet Chemicals • Began manufacturing high- • Entered the X-ray contrast Private Limited with Shahad intensity sweeteners - media sector, with a basic facility (Unit I) saccharin and its salts building block (5- NIPA) 1968 1970 2000 • Commenced semi- automated manufacturing •
Slide 15: Who we are
Who we are A specialty pharmaceutical and healthcare ingredient and intermediate company, offering niche products with an approach of “Collaboration, Development, Manufacturing” to CDMO business. 14
Slide 16: Blue Jet Healthcare at a glance
Blue Jet Healthcare at a glance 511 1,177.9 KL INR 10,299.9 mn INR 3,777.3 mn Commercialized product reaction capacity across Revenue (FY25) (19.9% EBITDA (FY25) (36.7% portfolio (FY25) 3 facilities (FY25) FY21-25 CAGR) margin) Key metrics INR 2,848 mn 3.97x 35.8% 30.9% Cash and Cash Equivalents + F
Slide 17: Overview of our Product Categories
Overview of our Product Categories Contrast Media High Intensity Pharma Intermediates Intermediates Sweeteners & APIs ◼ Contrast media are agents used in medical ◼ High-intensity sweetener business involves ◼ Collaboration with innovator pharmaceutical imaging to enhance the visibility of body tissu
Slide 18: Contrast Media Intermediates
3 Contrast Media Intermediates 17
Slide 19: Overview of Contrast Media and its growth drivers
Overview of Contrast Media and its growth drivers What is contrast media? Types of contrast media ◼ Chemical agents that enhances the contrast of an imaging ◼ X-ray / Computed Tomography (CT) contrast agents: Iodine- modality in diagnostic imaging, thereby aiding diagnosis of based contrast media ag
Slide 20: The global Contrast Media industry is highly concentrated
The global Contrast Media industry is highly concentrated Highly concentrated and dominated by multi-national corporations Player 1 Others 17% 25% Global Forecast US$9.7bn By 2029 Player 2 Collectively hold ~75% of the global sales of contrast 20% Player 4 (CAGR: 7.5%) media formulations1 11% Player
Slide 21: High entry barriers for key intermediates' vendors
High entry barriers for key intermediates’ vendors Characteristics of the Contrast Media Intermediate Blue Jet's positioning Contrast Media market product category performance ✓ More than two decades of experience CAGR: 3.4% ✓ 75%+ of exports of a selected contrast media Strict internal standards in
Slide 22: Key benefits
Continue to forward integrate into more advanced intermediates for Contrast Media Strong product development and process optimization capabilities underpinned by in-house R&D capabilities Capture larger wallet share with existing customers Focus on molecules with customer interest and strategy in ei
Slide 23: High Intensity Sweeteners
4 High Intensity Sweeteners 22
Slide 24: Blue Jet's positioning in High Intensity Sweetener
Blue Jet’s positioning in High Intensity Sweetener Blue Jet's positioning High Intensity Sweeteners product category performance Products ◼ Adherence to strict internal standards to ensure consistency in quality, performance, CAGR: 7.8% taste, and impurity profile Revenue (INR mn) ◼ Multiple product
Slide 25: Pharma Intermediates & API
5Pharma Intermediates & API 24
Slide 26: Trends and features of the Pharma Intermediates and APIs Product Category
Trends and features of the Pharma Intermediates and APIs Product Category Key trends in Pharma Intermediates and CDMO market Revenue and capacity utilization predictability Increased propensity to outsource manufacturing of intermediates & APIs for the CDMO ◼ Enables asset light model and ability to
Slide 27: Overview of Blue Jet's Pharma Intermediates and APIs Product Category
Overview of Blue Jet’s Pharma Intermediates and APIs Product Category Pharma Intermediate and APIs ◼ Commenced manufacturing pharma intermediates two decades ago, leveraging the customer relationships through high-intensity product category performance sweetener business ◼ Key focus areas include hi
Slide 28: Leverage long-standing customer relationships to enter adjacencies in pharma intermediates and API
Leverage our long-standing customer relationships to continue entering adjacencies in the pharma intermediate and API category Focus on three niche areas in providing CDMO services Blue Jet’s positioning Investigational new drugs and new chemical Leverage long-standing relationships with innovator e
Slide 29: R&D Capabilities
6 R&D Capabilities 28
Slide 30: Our R&D framework
Our R&D framework R&D capabilities across Process research Portfolio Process Process scale-up Regulatory filings evaluation development and validation and approvals Analytical research Chemistry research Method Characterization of Polymorphism Pharmaceutical salt High pressure Literature search deve
Slide 31: Sustainability
Sustainability Various initiatives on energy efficiency, renewable energy, and water conservation to reduce carbon footprint Invested in windmills with installed capacity of 3.3MW Created carbon sinks Focus on enhancing through tree plantations energy efficiency Effluent treatment plants with Minimi
Slide 32: Growth Strategy
ly. 7 Fe Growth Strategy
Slide 33: Our strategies
Our strategies Focus on operational efficiency and mitigation of supply chain risks Continue to forward integrate into Continue to invest in R&D more advanced intermediates for infrastructure and capabilities Contrast Media Leverage our long-standing Build additional production capacity customer rel
Slide 34: Management and Board of Directors
8 Management and Board of Directors 33
Slide 35: Experienced and visionary management team backed by independent Board of Directors
Experienced and visionary management team backed by independent - Board of Directors Management team Akshay Bansarilal Shiven Akshay Naresh Suryakant Shah Ganesh Vimalendu Kumar Singh Chandrashekar Parenky Arora Arora Executive Director, Head Karuppannan (V.K. Singh) President – Research and Executi
Slide 36: Management team and independent board of directors (cont'd)
Experienced and visionary management team backed by independent Board of Directors (cont’d) Management team (cont’d) Independent board of directors Popat B Kedar Sweta Poddar Girish Paman Preeti Gautam Divya Sameer Priyanka Yadav Executive Director Company Secretary and Vanvari Mehta Momaya Independ
Slide 37: Thank you!
Thank you! BLUE JET HEALTHCARE LIMITED INVESTOR RELATIONS AT Registered Office Blue Jet Healthcare Limited 701,702, 7th Floor, Bhumiraj Costarica, Sanjay Sinha, Deputy Chief Financial Officer Sector 18, Sanpada, Navi Mumbai Thane sanjay.sinha@bluejethealthcare.com 400705, Maharashtra, India NSE: BLU